StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Seres Therapeutics's enterprise value was -$852.65K on Nov 11, 2026, against $101.37M a year earlier. Over the last 5 years it ranged from -$5.96M to $664.49M, with a median of $103.12M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$852.65K-101.2%
2025Dec 31, 2025$74.11M+14.5%
2024Dec 31, 2024$64.74M-37.2%
2023Dec 29, 2023$103.12M-79.6%
2022Dec 30, 2022$506.37M+16.7%
2021Dec 31, 2021$433.77M-77.6%
2020Dec 31, 2020$1.94B+1129.9%
2019Dec 31, 2019$157.69M+41.2%
2018Dec 31, 2018$111.72M-53.4%
2017Dec 29, 2017$239.50M+22.1%
2016Dec 30, 2016$196.14M-83.0%
2015Dec 31, 2015$1.15B–

More Seres Therapeutics figures

See a number that looks wrong?